ETON vs. OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, ABCL, and IMCR
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs. Its Competitors
Ocular Therapeutix (NASDAQ:OCUL) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.
In the previous week, Ocular Therapeutix had 13 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 20 mentions for Ocular Therapeutix and 7 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.93 beat Ocular Therapeutix's score of 0.59 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
Ocular Therapeutix presently has a consensus price target of $22.63, indicating a potential upside of 101.47%. Eton Pharmaceuticals has a consensus price target of $29.67, indicating a potential upside of 58.05%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Eton Pharmaceuticals.
Eton Pharmaceuticals has lower revenue, but higher earnings than Ocular Therapeutix. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Eton Pharmaceuticals has a net margin of -7.10% compared to Ocular Therapeutix's net margin of -382.51%. Eton Pharmaceuticals' return on equity of -0.73% beat Ocular Therapeutix's return on equity.
Ocular Therapeutix has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
Summary
Ocular Therapeutix beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 10/14/2025 by MarketBeat.com Staff
